HOE-140 (Icatibant) |
B2R antagonist |
Approved |
Hereditary angioedema |
Shortened the duration of acute attacks |
[41] |
|
|
Phases I-IV |
Cardiopulmonary bypass, inflammation, fibrinolysis,
surgery, ischaemic heart diseases, ischaemic reperfusion, heart failure,
ACE inhibitor associated angioedema, angioneurotic edema |
Many
completed and ongoing studies. Decreased intraoperative fibrinolytic
capacity in cardiopulmonary bypass. No efficacy demonstrated for
angioedema and ischemia-reperfusion injury |
[45-47] |
|
|
Phase II |
Mitochondria and chronic kidney disease |
Completed, no
evidence of efficacy |
NCT03177798 |
|
|
Phase II |
Knee pain in osteoarthritis |
Completed, results not
available |
NCT00303056 |
MEN16132 (Fasitibant) |
B2R antagonist |
Phase II |
Knee pain in
osteoarthritis |
Two studies completed. No direct evidence of efficacy,
treated patients used less rescue medication. |
NCT01091116
NCT02205814 |